Substrate reduction therapy is another method for treating lysosomal storage diseases.[8] In this treatment, the accumulated compounds are inhibited from forming in the body of a patient suffering from a lysosomal storage disease.[8] The accumulated compounds are responsible for the symptoms of these disorders, and they form via a multi-step biological pathway.[8] Substrate reduction therapy uses a small molecule to interrupt this multi-step pathway and inhibit the biosynthesis of these compounds.[8] This type of treatment is taken orally.[8] It does not induce an unwanted immune response, and a single type of small molecule could be used to treat many lysosomal storage diseases.[8] Substrate reduction therapy is FDA approved and there is at least one treatment available on the market.[8]